While enalumab trials used eltrombopag, an expert would combine it with other TPORAs like avatrombopag in practice. This is due to similar mechanisms and superior tolerability profiles of alternatives (e.g., no dietary restrictions or hepatotoxicity risk).

Contrary to initial concerns, long-term safety data for thrombopoietin receptor agonists has allayed fears of malignant transformation and irreversible bone marrow fibrosis. The increased reticulin fibrosis observed is reversible upon drug discontinuation, offering significant reassurance for long-term prescribing.

The VEHIT2 trial protocol, combining yanalumab and eltrombopag shortly after steroid failure, represents a paradigm shift. It moves beyond sequential single-agent therapy to explore if early, potent intervention can fundamentally reduce the long-term severity and chronic nature of ITP.

Even if randomized trials show zongertinib's efficacy is merely comparable to chemoimmunotherapy, its significantly milder safety profile—especially its lack of cardiac toxicity and manageable side effects—is expected to make it the preferred first-line choice. Patient quality of life and tolerability are becoming decisive factors in treatment selection.

The treatment paradigm for ITP is shifting towards early combination therapy. Recent clinical trials are investigating augmented first- and second-line regimens, such as combining dexamethasone with rituximab or romiplostim, to achieve more durable, treatment-free responses than monotherapy.

Platelet aggregation studies show riluzobrutinib does not impair platelet function. This unique profile suggests it may not need to be stopped before surgery, avoiding the risk of a perilous drop in platelet counts for ITP patients—a key differentiator from other BTK inhibitors.

Pirtobrutinib is the first BTK inhibitor to show a rate of atrial fibrillation equivalent to a chemoimmunotherapy control arm in a randomized trial. This uniquely safe cardiovascular profile makes it a strong first-line candidate for older Chronic Lymphocytic Leukemia (CLL) patients or those with significant heart-related comorbidities.

Patients with ITP who fail or are intolerant to one TPO receptor agonist (e.g., eltrombopag) should not be considered a class failure. Switching to another TPO agent is a viable strategy that can induce a response in nearly half of these cases, particularly for intolerance.

To minimize steroid toxicity, a thrombopoietin receptor agonist (TPORA) should be the immediate second-line therapy for ITP patients who fail their initial course of corticosteroids. There is no need to trial multiple other therapies before considering a TPORA.